Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B surface antigen + Advax-2
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine composed of **hepatitis B surface antigen** (HBsAg)—the primary immunogenic protein component of the hepatitis B virus—and **Advax-2**, an adjuvant based on delta inulin polysaccharide. Advax-2 enhances and accelerates the humoral and cellular immune response to HBsAg, providing antigen dose sparing and improved seroprotection, especially in populations with historically lower vaccine responses such as individuals with chronic disease, renal impairment, or older adults. Compared with conventional alum-adjuvanted vaccines, Advax-2 increases anti-HBs antibody titers, broadens T-cell responses (Th1/Th2/Th17), and improves antibody affinity maturation, resulting in more robust and accelerated immunity. Advax-2 has been shown to be well tolerated in clinical studies and does not induce inflammasome activation. Its addition to hepatitis B vaccines is being developed as an advanced formulation to increase effectiveness, speed of protection, and coverage in low-responder populations[1][3][5].
- Other names
- hepatitis B vaccine based on hepatitis B surface antigen + Advax-2
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis B surface antigen + Advax-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B surface antigen + Advax-2.